KAS
APGE

Kemnay Advisory Services’s Apogee Therapeutics APGE Stock Holding History

Kemnay Advisory Services’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-430
Closed -$36.2K – 1187
2026
Q1 		$36.2K Buy
430
+312
+264% +$22.7K 0.01% 377
2025
Q4 		$8.91K Buy
+118
New +$7.43K ﹤0.01% 768

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Kemnay Advisory Services's APGE Position: Q2 2026 in Review

Kemnay Advisory Services sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 430 shares — an estimated $36.2K sold.

Kemnay Advisory Services first reported a position in APGE in Q4 2025 and held it in 2 quarters. The position peaked at $36.2K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Kemnay Advisory Services reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 430 Apogee Therapeutics shares in Q2 2026, an estimated $36.2K.
  • Kemnay Advisory Services first reported a position in Apogee Therapeutics in Q4 2025 and held it in 2 quarters.
  • Kemnay Advisory Services's Apogee Therapeutics position peaked at $36.2K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.